For instance, the combination of a FAK inhibitor (defactinib) that decreases tumor desmoplasia, anti-PD-1 (pembrolizumab), and gemcitabine demonstrated favorable safety profiles, promising initial efficacy, and exhibited biomarker activity in infiltrative T cells in PDAC within a phase I clinical investigation (NCT02546531) [320]. Here, PTK2 is linked to neoplasm.